Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis

Morie Gertz, Merrill D. Benson, Peter J Dyck, Martha Grogan, Terresa Coelho, Marcia Cruz, John L. Berk, Violaine Plante-Bordeneuve, Hartmut H J Schmidt, Giampaolo Merlini

Research output: Contribution to journalArticle

132 Scopus citations

Abstract

Transthyretin amyloidosis is a fatal disorder that is characterized primarily by progressive neuropathy and cardiomyopathy. It occurs in both a mutant form (with autosomal dominant inheritance) and a wild-type form (with predominant cardiac involvement). This article guides clinicians as to when the disease should be suspected, describes the appropriate diagnostic evaluation for those with known or suspected amyloidosis, and reviews the interventions currently available for affected patients.

Original languageEnglish (US)
Pages (from-to)2451-2466
Number of pages16
JournalJournal of the American College of Cardiology
Volume66
Issue number21
DOIs
StatePublished - Dec 1 2015

    Fingerprint

Keywords

  • familial amyloid cardiomyopathy
  • familial amyloid polyneuropathy
  • genetics
  • liver transplantation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gertz, M., Benson, M. D., Dyck, P. J., Grogan, M., Coelho, T., Cruz, M., Berk, J. L., Plante-Bordeneuve, V., Schmidt, H. H. J., & Merlini, G. (2015). Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. Journal of the American College of Cardiology, 66(21), 2451-2466. https://doi.org/10.1016/j.jacc.2015.09.075